Results 191 to 200 of about 754,759 (237)
Some of the next articles are maybe not open access.
Dengue vaccines: implications for dengue control
Current Opinion in Infectious Diseases, 2017Purpose of review Dengue, the most common arbovirus, is an increasingly significant cause of morbidity worldwide. After decades of research, an approved tetravalent dengue vaccine is finally available. Models constructed using recently available vaccine efficacy data allow for a data-driven discussion of the potential impact of
Matthew L, Robinson, Anna P, Durbin
openaire +3 more sources
Current Topics in Microbiology and Immunology
This chapter offers an overview of dengue vaccines that have advanced to clinical trials, addressing the intricate challenges in their development. It details the complexities of the dengue virus, including its four serotypes and the phenomenon of antibody-dependent enhancement (ADE), which significantly impacts vaccine design.
Silvia Beatriz Boscardin
openaire +3 more sources
This chapter offers an overview of dengue vaccines that have advanced to clinical trials, addressing the intricate challenges in their development. It details the complexities of the dengue virus, including its four serotypes and the phenomenon of antibody-dependent enhancement (ADE), which significantly impacts vaccine design.
Silvia Beatriz Boscardin
openaire +3 more sources
Dengue infection and advances in dengue vaccines for children
The Lancet Child & Adolescent Health, 2019Dengue viruses are endemic in most tropical and subtropical countries where they produce disease ranging from a mild fever to a severe, potentially fatal vascular permeability syndrome. We reviewed the status of development and testing in children of three vaccines designed to protect against the four dengue viruses.
Scott B, Halstead, Leonila F, Dans
openaire +3 more sources
Dengue vaccines: state of the art
Expert Opinion on Therapeutic Patents, 2010 Dengue is a significant public health problem transcending geographical boundaries to place nearly 50% of the global population at risk. A vaccine to prevent dengue is an unmet need that should be addressed urgently.A brief introduction to dengue and a detailed review of the classical and modern approaches being undertaken currently to develop dengue ...
Sathyamangalam, Swaminathan +2 more
openaire +3 more sources
Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines
Current Treatment Options in Infectious Diseases, 2023 Dengue viruses (DENV) continue to circulate worldwide, resulting in a significant burden on human health. There are four antigenically distinct serotypes of DENV, an infection of which could result in a potentially life-threatening disease.
Ashley L st john +2 more
exaly +2 more sources
Vaccine, 2020 Dengue fever, caused by dengue viruses (DENV 1-4) is a leading cause of illness and death in the tropics and subtropics. Therefore, an effective vaccine is urgently needed.
Zhaodong Liang, Maya Williams
exaly +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2008
Dengue is the most important mosquito borne virus infection in the tropics. Based on the effects of global warming, it is expected that dengue epidemic areas will further expand in the next decades unless effective and affordable vaccines are made available soon.
Scott B. Halstead, David W. Vaughn
openaire +3 more sources
Dengue is the most important mosquito borne virus infection in the tropics. Based on the effects of global warming, it is expected that dengue epidemic areas will further expand in the next decades unless effective and affordable vaccines are made available soon.
Scott B. Halstead, David W. Vaughn
openaire +3 more sources
Expert Review of Anti-infective Therapy, 2021
Introduction: Dengue virus is a global health threat, with approximately 390 million dengue infections annually. Efficient vaccines for dengue prevention are currently lacking. This review aims to summarize the current progress in dengue vaccine development.Area covered: This article discusses recent dengue vaccine developments based on the published ...
Chung-Hao Huang +4 more
openaire +2 more sources
Introduction: Dengue virus is a global health threat, with approximately 390 million dengue infections annually. Efficient vaccines for dengue prevention are currently lacking. This review aims to summarize the current progress in dengue vaccine development.Area covered: This article discusses recent dengue vaccine developments based on the published ...
Chung-Hao Huang +4 more
openaire +2 more sources
The Lancet, 2002
Every year there are several hundred thousand acres of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) resulting in thousands of deaths. The only method currently available to prevent dengue infections is the control of Aedes aegypti the mosquito vector. This approach has proved expensive and mostly unworkable.
Scott B, Halstead, Jacqueline, Deen
openaire +2 more sources
Every year there are several hundred thousand acres of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) resulting in thousands of deaths. The only method currently available to prevent dengue infections is the control of Aedes aegypti the mosquito vector. This approach has proved expensive and mostly unworkable.
Scott B, Halstead, Jacqueline, Deen
openaire +2 more sources
Vaccine, 2017
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers.
Ruth Aralí, Martínez-Vega +3 more
openaire +2 more sources
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers.
Ruth Aralí, Martínez-Vega +3 more
openaire +2 more sources